Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial

ABSTRACT: Endocrine therapy is recommended for patients with hormone receptor-positive (HR(+)) advanced and metastatic breast cancer without visceral crisis (symptomatic visceral disease). However, many patients experience disease progression during treatment, and most patients eventually develop en...

Descripción completa

Detalles Bibliográficos
Autor principal: Hortobagyi, Gabriel N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194611/
https://www.ncbi.nlm.nih.gov/pubmed/30340505
http://dx.doi.org/10.1186/s13058-018-1050-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6194611/
https://www.ncbi.nlm.nih.gov/pubmed/30340505
http://dx.doi.org/10.1186/s13058-018-1050-7

Ejemplares similares